New Licensing Partnership Spurs Plans for Phase 2 Study of Potential Therapy for Lupus Treatment
Alpine Immune Sciences, Inc. and AbbVie announced a partnership for an exclusive worldwide option and license agreement for a new drug therapy, ALPN-101, which inhibits two molecular pathways associated with autoimmune and inflammatory diseases. Through the partnership, Alpine is planning to conduct a Phase 2 study of the drug in lupus. AbbVie will take over responsibility to conduct all future clinical development, manufacturing and marketing of the drug.
The therapy has demonstrated efficacy in multiple preclinical disease models, superior to blocking either pathway alone, and favorable safety and tolerability, pharmacokinetics (drug absorption) and pharmacodynamics (biochemical/molecular effects on the body).
There is significant momentum across the research community for lupus research. This partnership is a promising example of that. Learn more about medications used to treat lupus.